BRPI0516168A - agente de formação de imagem upar, composição farmacêutica, e, método de geração de imagens de um corpo humano ou animal - Google Patents

agente de formação de imagem upar, composição farmacêutica, e, método de geração de imagens de um corpo humano ou animal

Info

Publication number
BRPI0516168A
BRPI0516168A BRPI0516168-1A BRPI0516168A BRPI0516168A BR PI0516168 A BRPI0516168 A BR PI0516168A BR PI0516168 A BRPI0516168 A BR PI0516168A BR PI0516168 A BRPI0516168 A BR PI0516168A
Authority
BR
Brazil
Prior art keywords
upar
human
pharmaceutical composition
animal body
imaging
Prior art date
Application number
BRPI0516168-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Alan Cuthbertson
Bente E Arbo
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of BRPI0516168A publication Critical patent/BRPI0516168A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0516168-1A 2004-09-29 2005-09-28 agente de formação de imagem upar, composição farmacêutica, e, método de geração de imagens de um corpo humano ou animal BRPI0516168A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20044139 2004-09-29
PCT/NO2005/000362 WO2006036071A2 (en) 2004-09-29 2005-09-28 Urokinase plasminogen activator receptor targeted contrast agent

Publications (1)

Publication Number Publication Date
BRPI0516168A true BRPI0516168A (pt) 2008-08-26

Family

ID=35930012

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516168-1A BRPI0516168A (pt) 2004-09-29 2005-09-28 agente de formação de imagem upar, composição farmacêutica, e, método de geração de imagens de um corpo humano ou animal

Country Status (11)

Country Link
US (1) US8568689B1 (enExample)
EP (1) EP1796733A2 (enExample)
JP (1) JP5122962B2 (enExample)
KR (1) KR101248350B1 (enExample)
CN (1) CN101065152A (enExample)
AU (1) AU2005287934B2 (enExample)
BR (1) BRPI0516168A (enExample)
CA (1) CA2580464A1 (enExample)
MX (1) MX2007003750A (enExample)
RU (1) RU2394837C2 (enExample)
WO (1) WO2006036071A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070190068A1 (en) * 2005-10-10 2007-08-16 Richard Hart uPAR-binding molecule-drug conjugates and uses thereof
US8273325B2 (en) * 2006-12-20 2012-09-25 Ge Healthcare As Contrast agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
DK2598175T3 (da) * 2010-07-27 2020-08-03 Serac Healthcare Ltd Radiofarmaceutiske sammensætninger
JP2015532636A (ja) * 2012-05-08 2015-11-12 リグスホスピタレト 部位特異的ｕＰＡＲ標的化のための１７７−Ｌｕ標識ペプチド
US9884131B2 (en) * 2012-12-03 2018-02-06 Curasight Aps Positron emitting radionuclide labeled peptides for human uPAR PET imaging
US20210138090A1 (en) * 2014-09-17 2021-05-13 Fluoguide A/S uPAR targeting peptide for use in peroperative optical imaging of invasive cancer
AU2015317444B2 (en) * 2014-09-17 2020-07-16 Fluoguide A/S uPAR targeting peptide for use in peroperative optical imaging of invasive cancer
RU2720976C2 (ru) * 2015-06-03 2020-05-15 Сюржимаб С.А.С. Флуоресцентные конъюгаты и их применение для диагностики опухоли
US11970554B2 (en) 2018-03-01 2024-04-30 Tonix Pharmaceuticals Holding Corp. Labeled oxytocin and method of manufacture and use
WO2021009219A1 (en) * 2019-07-16 2021-01-21 Fluoguide A/S A receptor-targeting conjugate with an effective pharmacokinetic profile
BR112022000164A2 (pt) * 2019-07-16 2022-04-12 Fluoguide As Conjugado de peptídeo direcionado a receptor de ativador de uroquinase-plasminogênio, composição farmacêutica, métodos para imageamento óptico e para detecção de uma doença, uso do conjugado de peptídeo ou da composição farmacêutica, e, kit de peças para a preparação de uma dosagem unitária
CN117412777A (zh) * 2020-12-01 2024-01-16 库拉赛特股份公司 尿激酶纤溶酶原活化剂受体靶向的放射性标记的肽缀合物
EP4277666A1 (en) * 2021-01-15 2023-11-22 Fluoguide A/S A upar (urokinase plasminogen activator receptor)-targeting conjugate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120765A (en) * 1993-04-02 2000-09-19 Shiseido Co. Ltd. Urokinase plasminogen activator fragments
US6277818B1 (en) * 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
GB9705521D0 (en) 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
AR020101A1 (es) * 1998-07-01 2002-04-10 Cancerforskingsfonden Af 1989 Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado.
US6896870B1 (en) * 1999-10-01 2005-05-24 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting uPA and uPAR
AU780730B2 (en) * 1999-10-01 2005-04-14 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting uPA and uPAR
RU2165266C1 (ru) * 2000-06-28 2001-04-20 Центральный научно-исследовательский рентгенорадиологический институт Способ получения [2-18f]-2-дезоксиглюкозы
US7763234B2 (en) 2004-03-04 2010-07-27 Ge Healthcare As Pharmaceutical compounds

Also Published As

Publication number Publication date
KR20070083604A (ko) 2007-08-24
AU2005287934A1 (en) 2006-04-06
JP2008514588A (ja) 2008-05-08
WO2006036071A3 (en) 2007-02-15
MX2007003750A (es) 2007-11-07
JP5122962B2 (ja) 2013-01-16
KR101248350B1 (ko) 2013-04-01
RU2007111467A (ru) 2008-11-10
EP1796733A2 (en) 2007-06-20
CA2580464A1 (en) 2006-04-06
US8568689B1 (en) 2013-10-29
RU2394837C2 (ru) 2010-07-20
CN101065152A (zh) 2007-10-31
WO2006036071A2 (en) 2006-04-06
AU2005287934B2 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
BRPI0516168A (pt) agente de formação de imagem upar, composição farmacêutica, e, método de geração de imagens de um corpo humano ou animal
Leucht et al. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended
Bryant et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract
SA521430342B1 (ar) تركيبة سائلة تشتمل على جسم مضاد لمستقبل ألفا إنترليوكين -4 البشري
Sarac et al. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo
BR112013015786A2 (pt) composição de agente de formação de imagem, método de formação de imagem de pelo menos uma parte de um indivíduo, e, método para preparar uma composição de polipeptídeo conjugado com quelante
BR0310088A (pt) Pré-direcionamento de droga por meio de anticorpos biespecìficos e constructos haptênicos compreendendo um veìculo peptìdico e o(s) agente(s) ativo(s)
BRPI0413977A (pt) método para suprimir um distúrbio neovascular, e para tratar um paciente diagnosticado com ou em risco de desenvolver um distúrbio neovascular, composição farmacêutica, e, embalagem farmacêutica
ECSP088203A (es) Dispersiones amorfas sólidas
PE20091852A1 (es) Formulacion farmaceutica que comprende un anticuerpo de ox40l
BR0317743A (pt) Dispositivo de liberação de agente ativo tendo membros de compósito
BR0308395A (pt) Sistema de exibição portátil
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
IL189948A0 (en) Y2 selective receptor agonists for therapeutic interventions
BRPI0702887A2 (pt) formulaÇÕes nutricionais contendo amido de tapioca modificado com octil succinato anidrido
BRPI0203172B8 (pt) composição farmacêutica para acondroplasia
BR0304269A (pt) Modelo estático para localização global
EP1702625A4 (en) A GENETICALLY MODIFIED ANTIBODY TO CHEMOKIN RECEPTOR-CCR4 CONTAINING MEDICAMENT
BRPI0410555A (pt) preparação sólida
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
MA29459B1 (fr) Vaccins
BRPI0416528A (pt) agente de formação de imagem, composição farmacêutica, composição radiofarmacêutica, conjugado, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
BR0200246A (pt) Tratamento de combinação para a depressão
MA31201B1 (fr) Compositions pharmaceutiques comprenant un agent calcilytique
BR0105776A (pt) Tratamento de combinação para a depressão,a ansiedade e a psicose

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2325 DE 28-07-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.